NVS Novartis AG

On September 18, Novartis AG (NYSE:NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Cosentyx (secukinumab) to treat polymyalgia rheumatica (PMR) in adults who respond inadequately to steroids or relapse during tapering. Following this recommendation, the European Commission is expected to issue a […]

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. It happened after three patients died from immune effector cell-associated hemophagocytic syndrome, a rare and severe immune reaction. […]

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)’ 20 largest shareholders, publicly called for a shake-up of the Swiss drugmaker’s board to improve oversight of its acquisitions, after Novartis shares suffered an 11% one-day drop this week. It wiped out nearly $30 billion in market value and erased all of […]

1432 GMT – UCB’s portfolio offers growth potential into the next decade after the acquisitions of Candid Therapeutics and Neurona, so the Belgian drugmaker’s next deals might target early-stage assets, Bank of America analysts say. Data due next year from a midstage trial of its galvokimig eczema drug candidate will likely inform UCB’s decision on whether it needs to add further late-stage medicines to its pipeline over time, the analysts say. UCB executives seemed confident at a Bank of America event that the company’s top-selling product Bimzelx can withstand competition from new drugs, the analysts say in a research note.

Novartis (SWX:NOVN) has signed an exclusive global license agreement with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset. The deal gives Novartis worldwide rights to develop and commercialise the BoomRay program as part of its radiopharmaceutical pipeline. The agreement adds another early stage oncology candidate to Novartis' radioligand therapy efforts, expanding its presence in targeted cancer treatments. This new BoomRay radioligand license sits within a wider pattern...

Novartis gained approval of a drug in IgAN with the same target as Roche’s sefaxersen in 2026.

Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]

While remigromig is non-inferior to Lucentis in terms of efficacy, questions around its tolerability remain.

VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.

Sefaxersen reduced proteinuria at 37 weeks, while kidney function and failure outcomes require longer observation.

Amgen Inc (NASDAQ:AMGN, XETRA:AMG)'s price target was raised to $410 from $367 by Jefferies after dazodalibep delivered positive Phase 3 results in patients with systemic Sjögren's disease. Jefferies said the drug, a CD40L antagonist, achieved a statistically significant and clinically...

1018 ET – Roche Holding is expected to move quickly to file for an accelerated approval for its sefaxersen drug candidate, a direct competitor to Novartis’s Fabhalta, RBC Capital Markets analysts say. The Swiss drugmaker reported positive interim results for a late-stage study of sefaxersen in autoimmune disease IgA nephropathy and the company had previously said it hoped the data would lead to an accelerated approval, consistent with the Fabhalta precedent, RBC says. “We think the muted reaction in [Roche] shares downplays the impact of a positive early interim readout from this study in an indication where we model [1.5 billion Swiss francs] in 2034 sales,” the analysts say in a research note.

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.

IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.

All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.

BoomRay focuses on radioligand therapies for precision oncology, spanning candidate discovery and clinical translation activities.

Britain’s biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research.

LONDON, Sept 22 (Reuters) - European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings ‌on Tuesday that the continent's pharmaceutical industry risks losing out to the ‌United States and China. Cash-strapped European governments have been under pressure for some time from lobby groups ​and drugmakers to rethink how they attract, nurture, value and pay for innovative medicines to avoid falling behind in an increasingly com

A private meeting with Amgen management left Morgan Stanley with a very different read than the broader market’s.

Novartis AG (NYSE:NVS) has discontinued development of VHB937, also known as lifonebart, after the experimental ALS drug failed to meet both its primary and secondary endpoints in a Phase II trial involving 251 patients with early-stage ALS. The drug targeted TREM2, a protein involved in immune responses and inflammation in the brain. Novartis will stop […]

NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.

Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...

Novo Nordisk's (NVO) US-listed shares declined as the Danish drugmaker unveiled its long-term growth

Shares in the company fell roughly 8% as its CEO laid out plans for new blockbuster drugs in the next few years.

Telix Pharmaceuticals announced a merger with privately held ITM on Monday, leading the stock to crash despite bullish views from analysts.

Investing.com -- European assets may offer investors advantages that are being overlooked as markets remain heavily focused on U.S. technology leadership, according to Macquarie Global Strategy, which sees structural changes supporting stronger European returns.

Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while acknowledging setbacks in late-stage cardiovascular studies. Monia said the company has secured two

Novartis (SWX:NOVN) agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease treatments. The deal gives Novartis control of Sironax's technology designed to transport therapeutics across the blood brain barrier. The transaction expands Novartis' toolkit for research into central nervous system disorders where treatment options remain limited. Novartis' move to secure Sironax's brain delivery platform sits against a wider backdrop our research...

Novartis (SWX:NOVN) is back in focus after the European Medicines Agency's CHMP issued a positive opinion for Cosentyx in polymyalgia rheumatica, highlighting both the product portfolio and the wider immunology pipeline. Recent trading has been choppy. The share price is down about 9.5% over the past month but still shows a 6.1% gain year to date, while the 1-year total shareholder return of 21.3% points to momentum that has been building over a longer stretch. Scan how Novartis fits into the...

Ionis Pharmaceuticals (IONS) is back in focus after partner Novartis reported that the pivotal Phase 3 Lp(a)HORIZON trial of pelacarsen failed to reduce major cardiovascular events despite sharply lowering Lp(a) levels. The pelacarsen setback comes after a sharp reset in sentiment. Ionis Pharmaceuticals has posted a 7-day share price return of negative 15.99% and a 30-day share price return of negative 21.59%. Despite this, the company still has a 5-year total shareholder return of 25.67%,...

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

On September 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for myotonic dystrophy type 1. It marked the company’s third clinical setback in a week following the earlier failure of cardiovascular drug pelacarsen […]

On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes. Analysts said Amgen’s olpasiran faces […]

On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) meant to lower a cholesterol-carrying particle called Lp(a), failed to reduce heart attacks, strokes and related cardiovascular events in the Lp(a)HORIZON trial, which enrolled more than 8,000 patients. The drug did lower Lp(a) levels […]

Key Stats for Amgen StockCurrent Price: $375. 65Target Price (Mid): ~$495Street Target: ~$388Potential Total Return: ~32%Annualized IRR: ~6.

Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.

Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.

TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart.

Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.

UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its buy rating on the FTSE 100 drugmaker even after two clinical setbacks and speculation about a mega-merger. The stock has fallen roughly 15% since early July, when two...

Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.

Legend’s new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International.

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

Ingrid Zhang is taking the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.

Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.

Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.

AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.

Palantir Technologies' (PLTR) AIPCon 11 highlighted growing demand for data sovereignty, with custom